

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/767,164	01/29/2004	John A. Hey	AL01678K	5520
24265 SCHERING-PI	7590 06/25/2007 LOUGH CORPORATION	I	EXAMINER	
PATENT DEPARTMENT (K-6-1, 1990)			CARTER, KENDRA D .	
	PING HILL ROAD H, NJ 07033-0530		ART UNIT PAPER NUMBER	
iceivie worth	11, 113 07033 0330	•	1617	
			· · · · · · · · · · · · · · · · · · ·	•
			MAIL DATE	DELIVERY MODE
			06/25/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)		
		10/767,164	HEY ET AL.		
Office Action Summary		Examiner	Art Unit		
		Kendra D. Carter	1617		
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address		
A SH WHI( - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAnsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).		
Status					
1)⊠	Responsive to communication(s) filed on 29 Ja	anuary 2004.			
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.				
3) 🗌	Since this application is in condition for allowar	•			
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.		
Disposit	ion of Claims	,			
5) □ 6) □ 7) □ 8) ⊠ <b>Applicat</b> i	Claim(s) 1-20 is/are pending in the application.  4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) is/are rejected.  Claim(s) is/are objected to.  Claim(s) 1-20 are subject to restriction and/or estimate in the specification is objected to by the Examine The drawing(s) filed on is/are: a) acceptable.	vn from consideration. election requirement. r. epted or b) □ objected to by the i			
	Applicant may not request that any objection to the o	- · ·	` '		
11)	Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Ex-				
Priority ι	under 35 U.S.C. § 119				
a)l	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the prior application from the International Bureau  See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive i (PCT Rule 17.2(a)).	on No ed in this National Stage		
Attachmen		<b></b>			
2) 🔲 Notic 3) 🔲 Infor	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) tr No(s)/Mail Date	4)	ate		

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

 Claims 1-14, are drawn to a method for treating or preventing an allergic skin condition or an allergic ocular condition administering one or more histamine H1 receptor antagonists and one or more histamine H3 receptor

antagonists to the subject, classified in class 514, subclass 1+.

II. Claims 15-20, are drawn to a combination comprising one or more

histamine H1 receptor antagonists and one or more histamine H3 receptor

antagonists, classified in class 424, subclass 451-483 for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions of Group I and II are related as product and process of use. The

inventions can be shown to be distinct if either or both of the following can be shown: (1)

the process for using the product as claimed can be practiced with another materially

different product or (2) the product as claimed can be used in a materially different

process of using that product. See MPEP § 806.05(h). In the instant case the method

of Group II can further comprise an antibiotic, NSAID, or/and a steroid.

Because these inventions are independent or distinct for the reasons given

above and there would be a serious burden on the examiner if restriction is not required

because the inventions have acquired a separate status in the art in view of their

different classification, restriction for examination purposes as indicated is proper.

Claims 1-20 are generic to the following disclosed patentably distinct species:

1) allergic skin condition;

2) allergic ocular condition;

3) histamine H1 receptor antagonist; and

4) histamine H3 receptor antagonists.

The species are independent or distinct because the read on various compounds

or conditions classified in different classes and/or subclasses. Applicant is required

under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is

traversed. Applicant is advised that a reply to this requirement must include an

identification of the species that is elected consonant with this requirement, and a listing

of all claims readable thereon, including any claims subsequently added. An argument

that a claim is allowable or that all claims are generic is considered nonresponsive

unless accompanied by an election.

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are

subsequently found allowable, withdrawn process claims that depend from or otherwise

require all the limitations of the allowable product claim will be considered for rejoinder.

Art Unit: 1617

<u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Application/Control Number: 10/767,164 Page 5

Art Unit: 1617

Applicant is advised that the reply to this requirement to be complete must

include (i) an election of a species or invention to be examined even though the

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims

encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To

reserve a right to petition, the election must be made with traverse. If the reply does not

distinctly and specifically point out supposed errors in the restriction requirement, the

election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not

patentably distinct, applicant should submit evidence or identify such evidence now of

record showing the inventions or species to be obvious variants or clearly admit on the

record that this is the case. In either instance, if the examiner finds one of the inventions

unpatentable over the prior art, the evidence or admission may be used in a rejection

under 35 U.S.C.103(a) of the other invention.

No phone call was made due the complexity of the election/restriction.

Conclusion

Application/Control Number: 10/767,164 Page 6

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kendra D. Carter whose telephone number is (571) 272-9034. The examiner can normally be reached on 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**KDC** 

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER